Chimera Biotec's Ron Wacker addresses ultra-high sensitive immunoassay technology at the Association for Molecular Pathology annual meeting
Ron Wacker, product manager at Chimera Biotec, addressed the advantages of the company's Imperacer biomarker detection technology at the Association for Molecular Pathology's 2006 Annual Meeting, November 17, at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida.
Imperacer makes biomarkers and other forms of antigens 1000 times easier to detect compared to standard immunoassays by producing a thousand-fold increase in sensitivity in blood and other biological samples.
"The introduction of Imperacer comes not a moment too soon, since many of the commercial and research applications are too insensitive for today's challenges in drug design and diagnostic," said Wacker.
"We designed Imperacer to help alleviate this problem".
Additionally, Imperacer improves the detection of illegal substance abuse in blood work.
"Imperacer changes the face of drug testing with a new approach to myostatin doping, and consequently opens new doors in drug testing," Wacker said.
As part of the research and development department within Chimera, Wacker played a vital role in developing Imperacer.
Wacker holds a master's degree in biology from the University of Bremen and a doctorate from the University of Dortmund.
The Molecular Pathology Annual Meeting began November 15 and ended November 19.
It featured workshops and seminars on the top issues affecting molecular technology today from some of the most distinguished physicians throughout the USA.
